Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297Product type:GuidanceProgramme:Technology appraisal guidanceExpected publication date: 28 July 2021
Palforzia for treating peanut allergy in children and young people (TA769)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 February 2022
Risdiplam for treating spinal muscular atrophy (TA755)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 December 2021
Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal) (TA749)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 December 2021
Secukinumab for treating moderate to severe plaque psoriasis in children and young people (TA734)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 October 2021
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) (TA714)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 July 2021
Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 December 2019
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 December 2019
Cochlear implants for children and adults with severe to profound deafness (TA566)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 March 2019
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years (TA554)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 December 2018
Dinutuximab beta for treating neuroblastoma (TA538)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 August 2018
Immunosuppressive therapy for kidney transplant in children and young people (TA482)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 October 2017
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 July 2017
Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) (TA302)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 November 2013
Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people (TA300)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 November 2013
Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder (TA292)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 July 2013
Tocilizumab for the treatment of systemic juvenile idiopathic arthritis (TA238)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 December 2011
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 January 2011
Human growth hormone (somatropin) for the treatment of growth failure in children (TA188)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 May 2010
Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years (TA131)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 November 2007
Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years) (TA38)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 March 2002
Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma (TA10)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 August 2000
KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 ID1336Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Fenfluramine for treating seizures associated with Dravet syndrome [ID1109]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lumacaftor with ivacaftor for treating cystic fibrosis in children aged 2 to 11 years old homozygous for the F508del mutation [ID1486]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy ID1587Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged under 18 with non-malignant diseases [ID3745]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Omburtamab for treating relapsed neuroblastoma [ID1664]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Fenfluramine hydrochloride for treating Lennox-Gastaut seizures in people aged 2 and over [ID1651]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID2715]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids in people aged 12 and over [ID2716]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Beremagene geperpavec for treating dystrophic epidermolysis bullosa in children, young people and adults [ID3959]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dupilumab for maintenance treatment of uncontrolled moderate to severe asthma in children 6 to 11 years [TS ID 10085]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Baricitinib for treating moderate to severe atopic dermatitis in children and young people aged 2 to 17 [TS ID 10639]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Darunavir plus cobicistat fixed dose combination for paediatric human immunodeficiency virus 1 infection [TS ID 10722]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Somatrogon for treating growth disturbance in children and young people aged 3 and over [ID5086]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Eflornithine for maintenance treatment of high-risk neuroblastoma after 1 therapy in people up to 21 years [ID4060]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people 1 to 17 years [ID 5104]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dupilumab for children with severe atopic dermatitis [TS ID 10434]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC